Reactions Weekly

, Volume 1760, Issue 1, pp 189–189 | Cite as

Radium-223-chloride/zoledronic acid

Osteonecrosis of the jaw: 2 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a report, two men aged 79 years and 66 years were described, of whom the 79-year-old man developed osteonecrosis of the jaw (ONJ) following treatment with zoledronic acid, and radium-223-chloride for metastases of prostate cancer. Whereas, the 66-year-old man developed ONJ following treatment with zoledronic acid, and worsening of the ONJ following treatment with radium-223-chloride for metastases of prostate cancer [not all dosages and routes stated; durations of treatments to reactions onsets not stated].

Case 1: The man, who had prostate cancer with bone metastases, started receiving second-line therapy with zoledronic acid 4mg and abiraterone acetate in May 2013. Zoledronic acid was stopped in September 2014. Thereafter, he received various treatments, which were stopped...


  1. Dionisi V, et al. Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases. Clinical Genitourinary Cancer 17: e612-e617, No. 3, Jun 2019. Available from: URL: - Italy

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations